Patients’ and hematologists’ concerns regarding tyrosine kinase-inhibitor therapy in chronic myeloid leukemia
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Cancer Research and Clinical Oncology"
DOI: 10.1007/s00432-018-2594-8
Abstract: PurposeTo explore patients’ and hematologists’ concerns regarding tyrosine kinaseinhibitor (TKI)-therapy and identify variables associated these concerns. Methods A cross-sectional questionnaire including 16 common issues related to TKI-therapy was distributed to adults with chronic myeloid leukemia… read more here.
Keywords: hematologists concerns; concerns regarding; tki therapy; patients hematologists ... See more keywords
Targeted therapies: Remembrance of things past — discontinuation of second-generation TKI therapy for CML
Sign Up to like & getrecommendations! Published in 2017 at "Nature Reviews Clinical Oncology"
DOI: 10.1038/nrclinonc.2017.11
Abstract: Data from the recent Stop 2G-TKI study confirm that around 60% of patients with chronic myeloid leukaemia who discontinue second-generation BCR–ABL1 tyrosine-kinase inhibitor (TKI) therapy after a sustained deep molecular response remain in remission for… read more here.
Keywords: tki therapy; second generation; discontinuation; tki ... See more keywords
Do persons with chronic myeloid leukaemia have normal or near normal survival?
Sign Up to like & getrecommendations! Published in 2019 at "Leukemia"
DOI: 10.1038/s41375-019-0699-y
Abstract: Recent clinical trial and population-based registry reports claimed survival of persons with chronic phase chronic myeloid leukaemia (CML) receiving tyrosine kinaseinhibitor (TKI) therapy, especially those achieving a complete cytogenetic response (CCyR; no detectable Ph-chromosome) and/or… read more here.
Keywords: tki therapy; persons chronic; therapy; survival persons ... See more keywords
The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma
Sign Up to like & getrecommendations! Published in 2018 at "British Journal of Cancer"
DOI: 10.1038/s41416-018-0104-z
Abstract: BACKGROUNDThe outcome of patients who progress on front-line immune-based combination regimens (IC) including immune checkpoint inhibitors (CPI) and receive subsequent systemic therapy is unknown.MethodsRetrospective analysis of consecutive patients with clear-cell mRCC who progressed on one… read more here.
Keywords: therapy; vegfr tki; tki therapy; combination therapy ... See more keywords
Frequency and Severity of Hypothyroidism During TKI Therapy in the Pediatric and Young Adult Population
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Pediatric Hematology/Oncology"
DOI: 10.1097/mph.0000000000002527
Abstract: Tyrosine kinase inhibitors that target vascular endothelial growth factor receptor [VEGFR-TKI] are a class of targeted therapies approved for treatment of several malignancies and are increasingly used in the pediatric population. Development of hypothyroidism during… read more here.
Keywords: young adult; vegfr tki; therapy; tki therapy ... See more keywords
Treatment Free Remission for Chronic Phase Chronic Myelogenous Leukemia Patients Who Stopped Tyrosine Kinase Inhibitor Therapy Due to Intolerance
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-129533
Abstract: Introduction: Chronic Myelogenous Leukemia (CML) is a myeloproliferative neoplasm that is often diagnosed in adults between the ages of 25-60. The outcome of the chronic phase CML has dramatically changed due to Tyrosine Kinase Inhibitor… read more here.
Keywords: treatment; remission; tki therapy; therapy ... See more keywords
Effect of high patient out-of-pocket (OOP) cost for oral tyrosine kinase inhibitors (TKIs) on survival in EGFR and ALK positive stage IV non-small cell lung cancer (NSCLC).
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.27_suppl.3
Abstract: 3 Background: Patients with EGFR+ or ALK+ NSCLC benefit from oral TKIs, but high patient OOP TKI costs could negatively impact survival by reducing likelihood of continuing TKI therapy. We assessed the association of high… read more here.
Keywords: egfr alk; oop; tki therapy; tki costs ... See more keywords
Efficacy of immune checkpoint inhibitor therapy in EGFR mutation-positive patients with NSCLC and brain metastases who have failed EGFR-TKI therapy
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.955944
Abstract: Background Few treatment options are available for brain metastases (BMs) in EGFR-mutant non-small cell lung cancer (NSCLC) that progress with prior EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy. This study aimed to evaluate the efficacy of… read more here.
Keywords: egfr tki; therapy; inhibitor; patients treated ... See more keywords
Adjuvant EGFR-TKI therapy in resected EGFR-mutation positive non-small cell lung cancer: A real-world study
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2023.1132854
Abstract: Background Although several clinical studies have laid the foundation for the adjuvant application of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), some questions remain unresolved. This real-world study aimed to address questions such as… read more here.
Keywords: egfr tki; tki therapy; tki; adjuvant egfr ... See more keywords
NCCN Guidelines Updates: Discontinuing TKI Therapy in the Treatment of Chronic Myeloid Leukemia.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of the National Comprehensive Cancer Network : JNCCN"
DOI: 10.6004/jnccn.2019.5013
Abstract: The NCCN Guidelines for Chronic Myeloid Leukemia (CML) criteria for discontinuation of tyrosine kinase inhibitor (TKI) therapy have not seen significant updates in the past year, but the current guidelines reinforce the safety of treatment… read more here.
Keywords: nccn guidelines; treatment; tki therapy; discontinuation ... See more keywords